MoonLake shares fluctuate as Phase 3 HS data show 62% HiSCR75 response at Week 40; FDA feedback supports potential path without new trials.
Importance Rank:
1
MoonLake shares fluctuate as Phase 3 HS data show 62% HiSCR75 response at Week 40; FDA feedback supports potential path without new trials.
Copyright © Louis Velazquez. All Rights Reserved.